the product in the database has an inactive status
indications:
Peptic ulcer of the stomach and duodenum, also with co-existing infectionHelicobacter pylori. [Intrusive oesophagitis in the course of gastroesophageal reflux and prevention of recurrent erosive oesophagitis] The Zollinger-Ellison team.
Composition:
1 enteral capsules contain 20 mg of omeprazole.
Action:
Proton pump inhibitor (H+-K+ ATP-ases) in the parietal cells of the stomach. It reduces the secretion of both hydrochloric acid, both basic and stimulated (regardless of the type of stimulus). After oral administration, Omeprazole is absorbed in the small intestine. Inhibition of hydrochloric acid secretion in the stomach occurs after 1 hour. Maximum concentration in the blood occurs within 1-3 hours after administration. It is almost completely metabolised in the liver. It is mainly excreted in the urine. T0,5 is on average 40 minutes.
Contraindications:
Hypersensitivity to omeprazole or other components of the preparation. The safety of the medicine in children has not been determined - the drug should not be used in children.
Precautions:
Use with caution in elderly patients with co-existing cardiovascular diseases.
Pregnancy and lactation:
It can be used during pregnancy and breastfeeding only when the benefit to the mother outweighs the potential risk to the fetus or breastfed infant.
Side effects:
Gastrointestinal tract: sometimes diarrhea, constipation, bloating (with abdominal pain), nausea and vomiting, transient liver dysfunction; very rarely, oral mucositis, candidiasis, pancreatitis; In individual cases, hepatitis (with jaundice or without), hepatic encephalopathy has been observed in patients with pre-existing severe liver disease. Skin: sometimes pruritus, skin rash, hair loss, erythema multiforme, hypersensitivity to light, excessive sweating. Nervous system: sometimes fatigue, sleep disorders, headache and dizziness, very rarely confusion and hallucinations, isolated cases of depressive disorders. Sensory organs: sporadic cases of misty vision and taste disorders; rarely, especially after intravenous administration of Omeprazole, blurred vision (blurred vision, loss of visual acuity, reduced vision, and even loss of vision), which may occur especially during long-term use of high doses and in patients with severe general condition with unstable cardiac insufficiency. Hypersensitivity reactions: urticaria in individual cases, fever, angioneurotic edema, bronchospasm or anaphylatic shock. Blood changes, reversible thrombocytopenia, leukopenia or pancytopenia, agranulocytosis have been reported sporadically. In addition: rare edema of the lower limbs, myasthenia gravis, muscle and joint pain; in isolated cases, interstitial nephritis and gynecomastia.
Dosage:
Orally. Duodenal ulcer: usually 20 mg once a day for 2-4 weeks; in severe cases and in relapses, the dose can be increased to 40 mg daily. Peptic ulcer: usually 20 mg once a day for 4-8 weeks; in severe cases and in relapses, the dose can be increased to 40 mg daily. Eczema esophagitis: usually 20 mg once a day for 4-8 weeks; in severe cases and in relapses, the dose can be increased to 40 mg daily. Zollinger-Ellison syndrome: 60 mg once a day, the duration of treatment depends on the patient's condition; in severe cases and in relapses, the dose may be increased to 80 mg / day; in more than 90% of patients with severe forms of the disease who did not show sufficient response to other treatments, the effective dose of 20-120 mg per day (doses of more than 80 mg per day should be administered in 2 doses). Patients with hepatic impairment should not be treated with doses higher than 20 mg daily. The capsules should be taken whole, before a meal, with liquid.
(C)
